Children born during the pandemic, including those exposed to COVID-19 in utero, were no more likely to screen positive for autism than unexposed or pre-pandemic children.
The 2024 Lasker-Bloomberg Public Service Award recognizes Quarraisha Abdool Karim and Salim S. Abdool Karim for global contributions to the fight against HIV/AIDS.
A new study reveals how Staphylococcus aureus bacteria adopt a different diet when colonizing the lungs, suggesting a new treatment strategy for these often dangerous staph infections.
When the virus arrived in New York City, VP&S clinicians were redeployed to areas in need, researchers pivoted to COVID research, and students graduated early to help “bend the curve.”
Front-line physicians, nurses, and staff at Columbia University Irving Medical Center have begun receiving the initial doses of the first COVID vaccines.
A study of more than 1 million patients has found no increased risk of COVID-19 diagnosis, hospitalization, or complications for users of two common anti-hypertensive medications.
Researchers at Columbia, UCLA, and Northeastern have begun helping the FDA in its effort to monitor the safety and effectiveness of vaccines, including COVID-19 vaccines, and other biologic products.
Columbia’s Evelyn Berger-Jenkins, MD, has co-authored new recommendations to help pediatricians address emotional and behavioral health issues in children during the COVID-19 pandemic.
On World AIDS Day, David Ho, MD, received the National Leadership Recognition Award from the National AIDS Memorial and spoke at a virtual event about the impacts of HIV/AIDS and COVID-19.
This year’s Crown Awards video celebrated our front line heroes—physicians, researchers, staff, students, and trainees—who have responded so valiantly to the COVID-19 pandemic.
A new nationwide study of more than 50,000 individuals—coordinated by Columbia researchers—is now underway to determine factors that predict disease severity and long-term health impacts of COVID-19.
Compared with adults, children produce a very different antibody response after infection with the new coronavirus, SARS-CoV-2, suggesting they clear the virus easily.